BridgeBio Oncology Therapeutics, Inc. Investment Banking Revenue
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Investment Banking Revenue of $1.16 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-01.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InvestmentBankingRevenue · last filed 2025-08-01
- BridgeBio Oncology Therapeutics, Inc. investment banking revenue for the quarter ending 2025-06-30 was $1.16K.
- BridgeBio Oncology Therapeutics, Inc. investment banking revenue for the quarter ending 2025-03-31 was $2.44K.
- BridgeBio Oncology Therapeutics, Inc. investment banking revenue for the quarter ending 2024-12-31 was $3.18K.
- BridgeBio Oncology Therapeutics, Inc. investment banking revenue for the quarter ending 2024-09-30 was $3.00K.
- BridgeBio Oncology Therapeutics, Inc. investment banking revenue for fiscal 2024 was $6.18K.
| Period end | Investment Banking Revenue 3 month | Investment Banking Revenue 6 month | Investment Banking Revenue 9 month | Investment Banking Revenue 12 month |
|---|---|---|---|---|
| 2025-06-30 | $1.16K 10-Q · filed 2025-08-01 | $3.60K 10-Q · filed 2025-08-01 | $6.79K derived: sum of 3 quarters · filed 2025-08-01 | $9.79K derived: sum of 4 quarters · filed 2025-08-01 |
| 2025-03-31 | $2.44K 10-Q · filed 2025-05-15 | $5.63K derived: sum of 2 quarters · filed 2025-05-15 | $8.63K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2024-12-31 | $3.18K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $6.18K derived: sum of 2 quarters · filed 2025-03-11 | $6.18K 10-K · filed 2025-03-11 | |
| 2024-09-30 | $3.00K 10-Q · filed 2024-11-14 | $3.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |